Update, 2026-07-23: the Pharmacy Compounding Advisory Committee met on July 23-24, 2026 as scheduled. FDA staff briefing documents recommended against adding any of the seven peptides on the agenda to the 503A Bulks List. No vote tallies have been published as of this update, and no peptide has been added to the Bulks List. See the final section for what changed since this piece was first written. The body below preserves the April 2026 status check as originally published.
Since early 2025, HHS Secretary Robert F. Kennedy Jr. has publicly signaled that a set of peptides previously removed from the Section 503A compounding pathway would be reviewed for reinstatement. The list commonly cited in press coverage is roughly 14 peptides — a figure that comes from Kennedy's own remarks rather than from any FDA document — including BPC-157, TB-500, MOTS-c, KPV, GHK-Cu, and melanotan II. The FDA action that followed in April covered 12 substances, not 14. Those statements generated a wave of "peptides are coming back in 2026" marketing from compounding clinics and longevity outlets — much of it outrunning what has actually happened on the regulatory record.
This piece is a sober, evidence-cautious status check as of 2026-04-17. The short version: the FDA removed 12 peptides from Category 2 on April 15 and published a meeting notice on April 16, the Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet on the question in July 2026 and again before the end of February 2027, and no peptide has yet been formally added to the 503A Bulks List under 21 CFR 216. Critically, leaving Category 2 is not the same as becoming compoundable. Every "becoming legal in 2026" headline that readers have seen is, at present, a prediction of what the advisory committee may recommend — not a description of current law.
What Kennedy / HHS actually announced
The most widely cited statement is Kennedy's February 27, 2026 appearance on The Joe Rogan Experience, during which he said the FDA was reviewing whether approximately 14 of 19 previously restricted peptides could be moved from the "Category 2" interim-designation holding pattern back to a status where 503A pharmacies could compound them. That is an executive-branch framing of intent — not a regulatory action.
The underlying regulatory reality is narrower. In 2023, the FDA placed a number of peptides into "Category 2" of the nominated-bulk-substances review, meaning the agency had identified safety concerns and 503A pharmacies generally should not compound them while the review continued. HHS does not bypass that review; the pathway to reinstatement runs through (a) the Pharmacy Compounding Advisory Committee reviewing each nominated substance, (b) FDA accepting or rejecting PCAC recommendations, and (c) notice-and-comment rulemaking before any substance is formally added to the 503A Bulks List codified at 21 CFR 216.23.
The 503A / 503B framework the reclassification would affect
Section 503A of the Food, Drug, and Cosmetic Act permits a state-licensed pharmacy to compound a drug using a bulk drug substance only if one of three conditions is met: the substance is the subject of a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on an FDA-published list of permitted bulk substances (the 503A Bulks List). Peptides without a monograph and without FDA-approval status — which is most of the named list — depend on the third pathway.
Section 503B governs outsourcing facilities and has its own separately maintained bulks list. None of the peptides under current PCAC consideration appear on either list today. The practical consequence is that a 503A pharmacy compounding BPC-157 or TB-500 in April 2026 is doing so outside the statutory pathway. A favorable PCAC vote in July 2026 would not change that status on the day of the vote; a Federal Register final rule adding the substance to 21 CFR 216.23 would.
What has actually published on the Federal Register
Two things published in mid-April, and they are routinely merged into one. On April 15, 2026, FDA updated its list of bulk drug substances nominated for use in compounding to remove 12 peptides from Category 2, effective within seven calendar days, on the stated ground that the original nominators had withdrawn their nominations. This is not a move to Category 1 and not an addition to the Bulks List. FDA has been explicit that removal from Category 2 does not by itself make a substance eligible for compounding, and none of the 12 was ever in Category 1 to return to. The 12 now sit outside Category 1, outside Category 2, and off the Bulks List — which leaves compounding them unlawful.
Then, on April 16, 2026 — one day before this piece's reference date — FDA published notice 2026-07361 in the Federal Register (Docket No. FDA-2025-N-6895), establishing a public docket and announcing a PCAC meeting on July 23–24, 2026 at FDA White Oak Campus. The docket closes for public comment at 11:59 p.m. ET on July 22, 2026. The notice identifies seven peptide-related bulk drug substances for the July agenda — BPC-157, KPV, TB-500, and MOTS-c on July 23; Emideltide (also called delta sleep-inducing peptide, DSIP), Semax, and Epitalon on July 24 — and indicates five additional peptides (cathelicidin LL-37, GHK-Cu, Dihexa, melanotan II, and PEG-MGF) for a second meeting before the end of February 2027.
This is a meeting notice, not a proposed rule and not a final rule. PCAC recommendations are advisory; FDA can accept, reject, or modify them. The formal rulemaking path — proposed rule → comment period → final rule adding a substance to 21 CFR 216.23 — has not begun for any peptide on the list.
What a formal rule would still have to address
Even if PCAC recommends inclusion, and FDA accepts the recommendation, several substantive questions remain unresolved in any public document. Acceptable dosage forms and concentrations would need specification. Whether the substance is added for 503A only, 503B only, or both has consequences for manufacturing scale. Permissible indications — BPC-157 was nominated citing ulcerative colitis, TB-500 citing wound healing — constrain the scope of what pharmacies can legitimately market. And USP monograph development, which usually lags regulatory permission, determines the analytical standards compounders must meet for identity, purity, and potency.
Readers should expect the PCAC transcripts in July 2026 to address dosage form and indication questions directly. What will not happen in July is an immediate change in legal status — that requires a subsequent, separately published final rule.
Implications for PeptaHub readers
Three practical framings. First, the distinction between the 12 peptides under review (BPC-157, TB-500, etc.) and FDA-approved prescription peptides like semaglutide and tirzepatide is not scheduled to collapse in 2026. Even under the most favorable PCAC outcome, compounded BPC-157 would enter a 503A patient-specific-prescription pathway, not an over-the-counter or research-chemical tier. Second, any product currently sold as "BPC-157" or "TB-500" in April 2026, outside a licensed 503A pharmacy with a valid prescription, is not legally compounded under any pathway. Announcement-driven marketing that implies otherwise is running ahead of the regulatory record. Third, readers tracking this closely should watch the Federal Register docket (FDA-2025-N-6895), the July 23–24 PCAC transcript when published, and any subsequent proposed rule citing 21 CFR 216.23 — that is the load-bearing document, not the press release.
PeptaHub's recovery pillar covers the underlying clinical evidence for BPC-157 and TB-500 independent of legal status, and our peptide legal-status guide walks through the 503A/503B framework in more depth. This piece will be updated when the July 2026 PCAC outcome is published and again if formal rulemaking begins.
Update — what changed since April 2026
The Pharmacy Compounding Advisory Committee met on July 23-24, 2026 at White Oak as scheduled, taking BPC-157, TB-500, KPV, and MOTS-c on the first day and emideltide (DSIP), Semax, and Epitalon on the second. The public comment window on docket FDA-2025-N-6895 closed on July 22.
FDA staff briefing documents recommended against adding any of the seven to the 503A Bulks List. The stated grounds were that none satisfied the criteria in 21 CFR 216.23(c), with the agency citing inadequate substance characterization, inconsistent naming conventions, missing quality data, insufficient or absent human clinical trial evidence, and safety flags including immunogenicity risk. That last cluster is worth noting for readers evaluating supply quality independently of the legal question: the agency's objection is partly that it cannot tell what these substances actually are as sold.
No vote tallies have been published as of this update, and nothing about the legal status of any peptide changed on the day of the meeting — which is what this piece predicted in April and remains the single most misreported aspect of the story. PCAC is advisory. Its recommendation binds no one. FDA must still decide whether to accept it, and codifying any substance onto the Bulks List at 21 CFR 216.23 requires notice-and-comment rulemaking that typically takes 12 to 24 months.
One further correction to how this story is commonly told. The figure of 14 peptides comes from Kennedy's February 2026 podcast remarks, not from any FDA document; the April action covered 12. Several substances routinely named in coverage as part of it were not — thymosin alpha-1, thymosin beta-4, ipamorelin, CJC-1295, AOD-9604, GHRP-2, and GHRP-6 all remain in Category 2 with no PCAC review scheduled. Note also that FDA named 'TB-500' specifically rather than thymosin beta-4, and that the agency's own reviewers flagged inconsistent peptide naming as a deficiency, so the two should not be treated as the same substance. The five remaining peptides from the April action — cathelicidin (LL-37), injectable GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF — are still scheduled for a second meeting before the end of February 2027.
PeptaHub maintains a per-compound regulatory status tracker and a full FDA peptide timeline that are updated as the record changes.